Reuters logo
BRIEF-Viiv Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen
December 19, 2016 / 11:52 PM / 10 months ago

BRIEF-Viiv Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen

Dec 19 (Reuters) -

* Viiv Healthcare announces positive results from first phase iii studies of two-drug HIV treatment regimen

* Safety profiles for Dolutegravir and Rilpivirine in these studies were consistent with the product labelling for each medicine

* Both phase III studies of Dolutegravir and Rilpivirine met the primary endpoint of non inferiority at week 48

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below